ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced it will host the first in a series of Key Opinion Leader (KOL) events on the emerging atopic dermatitis treatment landscape, and a review of the recently announced, positive topline data from its randomized, double-blind, placebo-controlled, 8-week, multiple-ascending-dose (MAD) Phase 1 study of ASLAN004 for the treatment of moderate-to-severe atopic dermatitis (AD). ASLAN004 is a potential first-in-class monoclonal antibody that targets the IL-13 receptor that has the potential for a differentiated profile in terms of convenience, safety and efficacy.

For more information, please refer to the press release.